Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC26A4 | O43511 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713157 | 1.00 | SLC26A4 (0.52) | SLC26A4KMT2AMEN1PTGS2BLM | |
| SCHEMBL29713112 | 0.89 | PTGS2 (0.61) | PTGS2LMNAHTTFFAR1POLB | |
| SCHEMBL24470813 | 0.89 | PTGS2 (0.61) | PTGS2LMNAHTTFFAR1POLB | |
| SCHEMBL31604962 | 0.84 | SLC26A4 (0.48) | SLC26A4KMT2AMEN1PTGS2BLM | |
| SCHEMBL30569416 | 0.78 | FFAR1 (0.40) | FFAR1 | |
| SCHEMBL31604955 | 0.77 | SLC26A4 (0.54) | SLC26A4KMT2AMEN1PTGS2BLM | |
| SCHEMBL31604932 | 0.74 | SLC26A4 (0.53) | SLC26A4KMT2AMEN1PTGS2BLM | |
| SCHEMBL31604970 | 0.73 | SLC26A4 (0.50) | SLC26A4KMT2AMEN1PTGS2BLM | |
| SCHEMBL29104695 | 0.73 | CYP2C19 (0.48) | PTGS2LMNAPOLBSMN1; SMN2 | |
| SCHEMBL1839725 | 0.72 | POLB (0.76) | SLC26A4KMT2AMEN1PTGS2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPV3, TRPM6, TRPM4 | SLC26A4 382/4885KMT2A 2278/4885MEN1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.